Table 2. Drug class identifications.
| Drug condition (mg, p.o.) | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| Placebo | Oxycodone | Dronabinol | |||||
|
|
|
||||||
| 30 | 60 | 5 | 10 | 20 | 30 | ||
| Placebo | 7 | 1 | 0 | 4 | 5 | 1 | 0 |
| Opiate agonist | 1 | 11 | 11 | 2 | 1 | 0 | 1 |
| Opiate antagonist | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Marijuana | 2 | 0 | 1 | 3 | 5 | 8 | 6 |
| Benzodiazepine | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Barbiturate | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Antipsychotic | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hallucinogen | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Other | 1 | 0 | 0 | 2 | 1 | 0 | 0 |
Values shown are the number of subjects identifying each drug class for each drug condition. “Other” represents a drug effect that the volunteer could not identify as belonging to a specific drug class. For each drug condition, n=12 except n=9 for dronabinol 30 mg. P.O. indicates oral route.